Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.31 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.31 |
| ▸ | PDE4A | P27815 | 1/20 | 0.31 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.31 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.31 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.31 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.30 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | GAPDH | P04406 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21396437 | 0.96 | TDP1 (0.60) | TDP1ADORA3ADORA1SIRT2SIRT1 | |
| SCHEMBL23921088 | 0.92 | TDP1 (0.55) | TDP1ADORA3ADORA1PDE4APDE4B | |
| SCHEMBL21396509 | 0.88 | TDP1 (0.53) | TDP1 | |
| SCHEMBL21396353 | 0.88 | TDP1 (0.60) | TDP1ADORA3ADORA1 | |
| SCHEMBL25930837 | 0.85 | TDP1 (0.58) | TDP1ADORA3ADORA1PDE4APDE4B | |
| SCHEMBL23921069 | 0.85 | TDP1 (0.56) | TDP1ADORA3ADORA1SIRT2SIRT1 | |
| SCHEMBL25932940 | 0.85 | TDP1 (0.55) | TDP1ADORA3ADORA1PDE4APDE4B | |
| SCHEMBL23920904 | 0.84 | TDP1 (0.53) | TDP1ADORA3ADORA1 | |
| SCHEMBL21396506 | 0.83 | TDP1 (0.55) | TDP1ADORA3ADORA1PDE4APDE4B | |
| SCHEMBL21396338 | 0.82 | TDP1 (0.58) | TDP1ADORA3ADORA1PDE4APDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190292214-A1 | NEW EQUATORIALLY MODIFIED POLYMER LINKED MULTIMERS OF GUANOSINE-3', 5'-CYCLIC MONOPHOSPHATES | MIRECA MEDICINES GMBH (DE) | 2019-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190292214-A1 | NEW EQUATORIALLY MODIFIED POLYMER LINKED MULTIMERS OF GUANOSINE-3', 5'-CYCLIC MONOPHOSPHATES | PDE7A, PRKG1, PDE4C | TDP1 1274/4885ADORA3 322/4885ADORA1 578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.